Recently, a new therapeutic strategy that targets blocking CCL11 signaling has shown significant improvement in patients with moderate-to-severe AD.[38] Immunoreactivity and transcripts of CCL11 were significantly increased in lesional skin from AD patients, but not in nonatopic controls.[39] Owczarek et al[40] showed that the average expression level of CCL11 gene in skin changes of AD patients was higher than that of unaffected skin. The gene discussed is CCL11; the disease is Alzheimer disease.